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Background: Newborn screening (NBS) for hemoglobinopathies is an effective first step to reduce 
morbidity and mortality of all affected newborns. The screening allows early detection and 
intervention of abnormal hemoglobin disorders. Children with sickle cell disease (SCD) are at 
increased risk for bacterial infections. Timely initiation of penicillin prophylaxis could reduce the 
morbidity and mortality of these invasive infections.   
Objective: The aim of the study is to determine the incidence rate of SCD in infants born in North 
Carolina and assess the effectiveness of penicillin prophylaxis within 3 months among these infants 
as well as evaluate the follow-up process.   
Methods: A retrospective analysis of infants with SCD identified through NBS from 2005-2009 was 
performed to identify penicillin initiation rate within 3 months of age as recommended by the state 
program guidelines. Age (in days) at time of penicillin initiation was calculated using birth and 
initiation dates. Incidence and detection rates were also computed. Characteristics were compared 
using the Kruskal-Wallis test.   
Results: In total, 590 North Carolina infants were identified with a hemoglobin disorder. Of the 590 
infants, 475 (81%) were diagnosed with SCD. A 5-year incidence of SCD among North Carolina live 
births was 74.32 per 100,000 or 1 in every 1,346 births. The incidence of SCD in black births was 
higher than other race/ethnic groups with 1 SCD baby in every 343 births. Based on these data, 457 
infants with SCD were analyzed in the initiation of penicillin prophylaxis by 3 months of age. There 
was a highly significant difference between the time to initiate penicillin within 3 months among the 
13 regions in North Carolina during this 5-year period (89.3% vs. 10.7%, p=0.002). However, there 
was no statistical significance in the incidence of SCD over the 5 years. Seven deaths (1.5%) 
occurred during this time period, with 1 SCD death (0.2%) related to pneumonia.  
Conclusion: The findings from this study support universal NBS and early intervention of penicillin 
prophylaxis. Public health leaders are urged to develop a greater focus on the importance of trait 
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counseling, as well as education concerning the role of NBS and the importance of prophylactic 
penicillin for infants with SCD. Further studies should be directed toward adherence of penicillin 
therapy within 3 months of age for children with SCD and measures to track infants currently lost to 
follow-up.  
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Sickle cell disease (SCD) is a chronic disorder of the red blood cells associated with a 
range of health problems, including an increased risk of sepsis, strokes, acute chest syndrome, 
pain crises, and premature death. The presence of abnormal hemoglobin causes the red blood 
cells to change from a normal round shape to a crescent/sickle shape. SCD has become an 
important public health issue in the United States with an estimated 90,000 to 100,000 people 
affected with sickle cell disease (Centers for Disease Control and Prevention [CDC], 2011).  It is 
estimated that about 2000 babies in the United States are born with sickle cell disease annually 
(American Academy of Pediatrics [AAP], 2002). Approximately 100 babies with SCD are born 
each year in North Carolina. The disease mostly occurs in about 1 out of every 500 
African American births. SCD also affects Hispanic Americans with more than 1 out of every 
36,000 births (CDC, 2011). In addition, it is estimated that 35% of children with SCD died as a 
result of sickle cell-related complications in the first 3 years of life prior to the introduction of 
newborn screening (Gaston, Verter, Woods, Pegelow, Kelleher, Presbury, Lobel, 1986).  
Sickle cell disease, characterized by the presence of sickle hemoglobin (Hb S) in the red 
blood cell, is a common example of a genetic determinant of health (Sickle Cell Disease 
Guideline Panel, 1993). It is a condition that infants inherit when both parents carry the sickle 
cell gene. In addition, approximately 2 million Americans have the sickle cell trait (CDC, 2011) 
in which an infant can get one copy of the gene from each parent. The gene is most commonly 
prevalent in people with families from African countries, Mediterranean countries, South or 
Central American countries, Caribbean islands, India, and Saudi Arabia. The most common and 
severe genetic type of SCD is sickle cell anemia affecting mostly African Americans, but the 
disease also strikes persons of other racial and ethnic backgrounds (CDC, 2011; Wethers, 2002). 
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Thalassemia is another genetic hemoglobin disorder characterized with only fetal (Hb F) 
hemoglobin and no detectable normal hemoglobin (Hb A). Newborns identified through 
screening with thalassemia need immediate follow-up for confirmatory testing to determine 
hereditary persistence of fetal hemoglobin, or beta-thalassemia major. The most common type of 
thalassemia is beta-thalassemia major (Cooley’s Anemia Foundation, 2010). This disorder causes 
severe anemia, bone expansion, and failure to thrive in infants. Most newborn screening 
programs in the U.S that include testing for non-sickle hemoglobin disorders have systems in 
place to ensure affected
 
newborns are referred to a comprehensive care program for ongoing care 
(Hoppe, 2009). Therefore, infants diagnosed with thalassemia in North Carolina are immediately 
referred to a comprehensive medical center for clinical care. The most common treatment for the 
major forms of thalassemia is red blood cell transfusions. These transfusions are necessary to 
provide infants with a temporary supply of healthy red blood cells. Early intervention for infants 
identified with thalassemia can improve their health outcome.  
Currently in North Carolina, the Sickle Cell Syndrome Program (NCSCSP) does not 
provide long-term care coordination for thalassemia disorders. Coordinating all the necessary 
care that includes social services, education, public health services, home visits, health care 
services, referrals and resources is a small part of general maintenance for infants with these 
disorders. Therefore, it should be recommended that the NCSCSP should coordinate long-term 
care for thalassemia by ensuring that children receive optimal and appropriate health care. 
Helping children with thalassemia and their families manage the daily needs of living with such 
a chronic disease is very important. If the NCSCSP embarks on long-term care coordination for 
thalassemia, they will have to request additional state funding. Nonetheless, further discussion of 
this issue is outside the scope of this paper. 
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Sickle cell hemoglobinopathies and its impact on public health: Sickle cell disease is a 
major public health concern because it is an inherited disorder that has a great impact on both 
individuals and the general public (CDC, 2011). From a standpoint of cost of care with SCD, the 
substantial costs sickle cell patients incur due to large number of hospital admissions, emergency 
room visits, and outpatient visits can be burdensome.  Studies revealed that a small proportion of 
patients tend to account for a majority of the total healthcare costs (Nietert, Silverstein, & 
Abboud, 2002). In 2005, as reported by Mvundura and colleagues, annual medical expenditures 
for children with SCD in the United States averaged $11,075 for children with Medicaid 
coverage and $14,722 for children with employer-sponsored insurance. About 40% of both 
groups had at least one hospital stay. Therefore, the total pediatric medical costs from SCD in the 
United States were estimated to be at least $335 million per year (Mvundura, Amendah, 
Kavanagh, Sprinz, Grosse, 2009). 
Importance of newborn screening and follow-up: Early screening and intervention for 
newborns diagnosed with SCD and other blood related disorders have reduced childhood 
mortality and morbidity (National Institutes of Health [NIH], 1987). Newborn screening (NBS) 
for sickle cell hemoglobinopathies was made available to targeted populations in 1972 when the 
Sickle Cell Anemia Control Act established the first federal legislation dealing with genetic 
diseases (Sickle Cell Disease Association of America, 2011). Although targeted screening for 
hemoglobinopathies has been available for years, there was some controversy on whether NBS 
should be targeted or universal. Some of the reasoning focused not only on the costs, but that 
early diagnosis did not present health benefits and little could be done to improve outcomes once 
detected (NIH, 1987). In addition, there was uncertainty about who should be tested.  The main 
purpose of NBS is to identify infants with a hemoglobin disorder or carrier status. Targeted 
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screening to specific racial and ethnic backgrounds can miss some affected infants, placing them 
at an increased risk for early onset of complications or even death (Sickle Cell Disease Guideline 
Panel, 1993). 
No matter what the screening outcome; it has been known that infants identified with 
SCD have an increased susceptibility to bacterial infection. Therefore, this led to a 1986 
landmark randomized-controlled study that demonstrated penicillin prophylaxis noticeably 
reduced the incidence of pneumococcal infections among children with sickle cell anemia 
(Gaston et al., 1986). This study provided the rationale and influential incentive for the 
widespread implementation of universal NBS for SCD.  Others found that when NBS was  
linked to timely follow-up for treatment before the onset of disease processes, parental education 
and counseling, and comprehensive care, NBS notably reduced morbidity and mortality 
associated with sickle cell disease in infancy and early childhood (Vichinsky, Hurst, Earles, 
Kleman, & Lubin, 1988).  
While the survival of children with SCD has improved past 5 years of age, some still 
remain at risk of premature death (Quinn, 2010; CDC, 2011). With early detection and use of 
public health interventions such as penicillin, education and counseling, along with 
comprehensive care, some of these deaths can be prevented. In 1973, the State of North Carolina 
passed House Bill 32 (General Statutes 143B-196), which established the statewide NCSCSP to 
oversee the provision of NBS and confirmatory testing, follow-up, education, genetic counseling, 
psychosocial support, and referral to specialty care services for patients diagnosed with SCD and 
other abnormal hemoglobin disorders (NCSCSP, 2010).  
To protect newborns from certain disorders and other serious health problems, North 
Carolina state law (General Statutes 130A-125) requires all infants born in North Carolina be 
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screened unless a parent decides to opt-out in writing (Public Health Law, 1983). According to 
the law, the attending health care providers are responsible for informing parents about newborn 
screening and collecting the sample. Optimally, the sample should be collected between 48-72 
hours after birth or prior to leaving the hospital or birthing centers. For home births, all licensed 
professionals attending a birth should collect the NBS sample. The screening test is conducted at 
the State Laboratory of Public Health (SLPH), as required by state law (North Carolina Division 
of Public Health, 2010). In May of 1994, universal NBS for hemoglobinopathies in North 
Carolina began for all infants born in the state.  
The screening for sickle cell disease and other abnormal hemoglobinopathies is an 
effective first step to reduce morbidity and mortality of all affected newborns. The screening 
allows early detection and surveillance of hemoglobin disorders as well as the option for early 
preventive measures. The follow-up program for sickle cell and other blood related disorders is 
located in the Division of Public Health, Sickle Cell Syndrome program.  This program oversees 
short and long-term follow-up of infants identified through NBS. Follow-up begins with 
notification of the infant’s health care provider followed by referring these infants and their 
family to an educator counselor and a comprehensive medical center in their areas for 
prophylactic penicillin treatment and care services. The program also maintains a follow-up 
database for monitoring and evaluating of services provided. Vichinsky et al (1988) noted that 
the value of specific follow-up program for SCD, particularly after identification by newborn 
screening, impacted mortality rates.  Specifically, they found 1.8% died in a group of children 
who were identified as having SCD as determined by NBS, compared to an 8% mortality rate in 
those diagnosed with SCD after 3 months of age.  Further, Vichinsky et al found this difference 
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in survival resulted not only from early diagnosis and treatment, but also from parental education 
coupled with routine follow-up care. 
Healthy People 2020 and hemoglobinopathies: “Healthy People provides science-based, 
10-year national objectives for improving the health of all Americans” (healthypeople.gov, 
2011). In 2010, the U.S. Department of Health and Human Services released Healthy People 
2020 (HP 2020), which contains new 10-year goals and objective. Based on the review process 
for Healthy People 2010, several new areas of health were included in HP 2020. One new area is 
titled “Blood Disorders and Blood Safety” (BDBS) and relates to hemoglobinopathies. In 
particular, objective BDBS-6 is “to increase the proportion of children with sickle cell disease 
who receive penicillin prophylaxis from 4 months to 5 years of age” (healthypeople.gov, 2011). 
In North Carolina, penicillin prophylaxis is administered as early as age three months continuing 
to five years (NCSCSP, 2010). It is generally discontinued at age five unless the child has had a 
spleen removal or severe history of pneumococcal infection. The state also collects data on long-
term follow-up of children with confirmed newborn sickle cell conditions. Follow-up of these 
children is undertaken to ensure that they receive the full benefits of early identification of sickle 
cell disease and other hemoglobin disorder through available intervention and services. 
The purpose of this paper is to determine the incidence of sickle cell disease in infants 
born during 2005 to 2009, assess the effectiveness of penicillin prophylaxis within 3-months of 
age with the goal of improving health outcomes, and evaluate the follow-up process for 
newborns with SCD in North Carolina. Tracking the benefits of early identification through 
newborn screening is also important for public health, since early identification affects long term 
outcomes for these children. 
 




In order to better understand the importance of early intervention of penicillin 
prophylaxis, it is necessary to conduct a literature review to examine newborn screening for 
sickle cell disease and other hemoglobin disorders along with the need for follow-up services. 
The PubMed (MEDLINE) and Google Scholar databases were searched systematically from 
1986 to 2011 for topics using the medical subject heading (MeSH) terms and key words to 
identify relevant articles. The following key words were used in different combinations: 
“newborn screening”, “hemoglobin”, “sickle cell anemia/disease”, “diagnosis”, 
“therapy/treatment”, “penicillin”, “follow-up”, “clinical management”, and “education”. The 
abstracts of these articles were obtained and reviewed to determine relevance to this paper. The 
search results were narrowed by eliminating articles that did not provide an overview of newborn 
screening practices, penicillin prophylaxis treatment, and comprehensive follow-up care for 
sickle cell hemoglobinopathies. Any relevant references were stored in RefWorks, a citation 
manager. In addition, reference lists in retrieved articles were also checked to identify additional 
articles, books, and websites that would be applicable to this paper, even though some are not 
directly related to North Carolina, these literature sources were included to give a sense of what 
is happening in other states and countries. 
Framework for sickle cell screening: Historically, children born with sickle cell disease 
have increased vulnerability to severe bacterial organisms, especially Streptococcus pneumoniae 
and Haemophilus influenza that can lead to life-threatening infections (Gaston et al., 1986; Gill, 
Sleeper, Weiner, Brown, Bellevue, Grover, Pegelow, & Vichinsky, 1995). Several studies, 
particularly the landmark Prophylactic Penicillin Study (PROPS), demonstrated the benefits of 
oral penicillin prophylaxis in infants with sickle cell disease (Gaston et al., 1986; Gill et al., 
1995). As stated above, the multicenter, randomized, controlled trial by Gaston et al (1986) 
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involved 105 infants in the penicillin group and 110 in the placebo group to determine whether if 
daily administration of oral penicillin would reduce the risk of pneumococcal septicemia. The 
study showed an 84% reduction in the incidence of Streptococcus pneumonia infection in infants 
treated with penicillin compared to infants in the placebo group, a statistically significant result 
which led to the study to be terminated eight months early (Gaston et al, 1986). Hence, this 
drastic reduction demonstrated the need to diagnose babies at birth and initiate penicillin 
prophylaxis.  
The publication of the findings from the PROPS study convinced the National Institute of 
Health (NIH) to convene a 1987 Consensus Conference to address issues related to newborn 
screening for sickle cell disease and other hemoglobinopathies. The conference group believed 
that the peril to health was so great that they recommended universal newborn screening for 
hemoglobinopathies to prevent life-threatening infections and severe complications from sickle 
cell disease (NIH, 1987). Early detection of sickle cell disease through newborn screening helps 
to reduce deaths and other complications. The screening for sickle cell disease became an 
important part in launching this prevention approach for the initiation of penicillin prophylaxis. 
According to NIH’s National Heart, Lung, and Blood Institute clinical guideline, The 
Management of Sickle Cell Disease, infants identified with sickle cell through newborn 
screening should receive oral penicillin prophylaxis from age 2 months until at least age 5 years 
in conjunction with standard immunization (NIH, 2002).  However it should be noted that the 
framework for screening for sickle cell and other hemoglobinopathies was first recommended in 
1987 and then in 2002, but that it was only instituted in all states in the United States, Puerto 
Rico, and the Virgin Islands as of May 2006 (Benson & Therrell, 2010). Several confirmatory 
recent studies have shown the effectiveness of NBS and active follow-up (King, Fraser, Forbes, 
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Grindley, Ali, & Reid, 2007; Frempong & Pearson, 2007; Lerner, Platania, & LaBella, 2009). 
The mechanism for follow-up activities, if results indicate an abnormal disorder in these NBS 
studies, includes informing providers and parents, confirmatory testing, treatment with 
prophylaxis, pneumococcal vaccination, parental education and genetic counseling, and referral 
to hemoglobinopathy treatment centers. These studies also found a reduction in mortality rate 
among children with SCD due to newborn screening and early interventions. Overall, these 
studies demonstrated the need for comprehensive follow-up care and services for these infants 
and parents to improve their early health maintenance regimen and outcome. The success of a 
NBS program for any disease depends not only on the number of infants diagnosed, but on the 
timely fashion in which these infants receive appropriate follow-up care. 
METHODS 
Data Collection Process: In this paper, data were collected from two databases: the 
North Carolina State Laboratory of Public Health (SLPH) Newborn Screening Program and the 
North Carolina Sickle Cell Syndrome Program (NCSCSP). The NCSCSP is a program that offers 
comprehensive services for individuals and their families affected by sickle cell disease and 
other hemoglobin disorders through its system of nine state regional educator counselors, six 
comprehensive medical centers and four community-based organizations. The program uses a 
web-based database system that collects and stores data (i.e. blood screening results, diagnosis, 
date treatment started, assessment, type of visits, etc.) concerning infants followed by the 
program. For this study, the data collection process began with SLPH’s identification of 
hemoglobin disorders of infants born in North Carolina via NBS from the time period of January 
2005 to December 2009. Following the identification of these infants, the study cohort who 
consisted of North Carolina resident births born during this time period was matched to the 
NCSCSP database to extract penicillin start dates and initial follow-up activity. The study cohort 
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did not include infants from other states who moved to North Carolina. Once the information 
was collected, the data were collated, summarized and de-identified for analysis. North Carolina 
vital statistics data were also used to obtain live birth and death information. The Institutional 
Review Board of UNC-Chapel Hill approved the secondary analysis of these de-identified data 
and determined this study was non-subject research and did not require further review and 
approval (UNC IRB determination 11-1430). In addition, a data use agreement (DUA) between 
the University of North Carolina at Chapel Hill and North Carolina Division of Public Health 
was developed and all parties signed. 
Detection of hemoglobin disorder by screening: All newborns born in North Carolina 
are screened by collecting a dried blood spot sample that is sent to the SLPH for initial screening. 
The test for detecting hemoglobin variants in North Carolina is typically performed using both 
isoelectric focusing and high-performance liquid chromatography (HPLC) methodology. Based 
on the Agency for Health Care Policy and Research (AHCPR) recommendation, hemoglobin 
electrophoresis, isoelectric focusing, and high performance liquid chromatography are accurate 
and cost-effective methods for newborn screening (Sickle Cell Disease Guideline Panel, 1993). 
These methods have been shown to detect hemoglobin (Hb) F, S, C, E, A, and variants. 
All initial newborn screening results indicative of a hemoglobin disorder, usually within 2 
weeks, are referred to the statewide program coordinator for notification and additional testing. 
A whole blood sample, instead of a blood spot, is obtained to perform a hemoglobin 
electrophoresis analysis for confirmation. It is also recommended that a family study be 
performed which includes both parents being tested. The presumptive hemoglobin genotype 
patterns of both initial and repeat testing for this study were determined by: FS and FSA, 
indicating Hb SS, Hb S-HPFH, or Hb S-beta thalassemia; FSC, indicating Hb SC; FSE, 
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indicating Hb SE; FSV, indicating Hb S-Variant (variant can be D-Los Angeles, Lepore, O-
Arab); FC, indicating Hb CC, Hb C-HPFH, or Hb C-beta thalassemia; FE, indicating Hb EE or 
Hb E-beta thalassemia; FCV, indicating Hb C-Variant; FV, indicating homogenous variant of D-
Los Angelos, Lepore, O-Arab; and FF, indicating beta thalassemia major or beta thalassemia 
minor.  
Follow-Up Process: To evaluate the newborn screening and follow-up process, data for 
this analysis was limited to infants with SCD. Since timely follow-up is important, the NCSCSP 
uses a comprehensive system that covers all 100 counties in North Carolina and is divided into 
13 regions (Appendix A). Each region has 9 state staff educator counselors and 4 community 
based organizations that are responsible for all follow-up activities. The activities consist of 
notifying the primary care provider and parents of the infants with a positive initial screening. 
The goal is to arrange for confirmatory testing of the infant within four weeks of age and 
complete a family study. These infants become part of the regional educator counselor’s caseload 
to ensure penicillin prophylaxis is started by 3 months of age based on the NCSCSP guidelines 
for administration of prophylactic penicillin (Appendix B).  The infant and their family are 
referred to a comprehensive medical center, according to recommended state program 
guidelines. Parental education and counseling are also offered to the families of the infant with 
SCD. 
Data Analysis: Data were entered in Microsoft Excel 2010 and analyzed in Statistical 
Analysis System (SAS, version 9). Incidence rates were calculated as the number of infants with 
hemoglobin disorder per 100,000 live births screened. Descriptive statistics were presented as 
percentages and means. A Kruskal-Wallis analysis was performed for comparison to test for 
statistical significance in the 5-year period. The Kruskal-Wallis is a non-parametric test used for 
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the comparison of more than two independent samples and can be applied in samples of unequal 
size. It is an appropriate statistical test for data lacking a normal distribution and/or containing 
outliers, since this test evaluates the degree to which to group means differ based on ranks rather 
than on the raw measures.  A p-value of 0.05 or less was considered a statistically significant 
result.  
RESULTS 
From January 2005 to December 2009, 639,115 North Carolina resident live birth infants 
were screened for hemoglobinopathies through the North Carolina SLPH. Of the 639,115 infants 
tested, 590 were identified with presumptive results of disease and formed the data to be 
analyzed. Ten (1.7%) of these infants could not have timely follow-up completed: 7 infants were 
not residents of North Carolina and were lost to follow-up; 2 infants were transfused at birth; and 
1 had an inconclusive blood test. Therefore, these infants were excluded from further analysis. It 
is important to note the impact of the initial screening in each of these 3 cases that remained in 
state, as the hemoglobin pattern was later identified as disease. The one case with a “not 
definitive” result was repeated in 2 months with a finding of FV and later found to be a benign 
condition. The other two cases, where one was reported as FAS- sickle cell trait, received red 
blood cell transfusion before the NBS test. It is known, that transfusion can report false-negative 
results so repeat testing must be done in 4 months.  Confirmatory test of these two transfused 
cases later showed results of FS and FSC. The remaining 580 (98.3%) infants identified 
consisted of 475 (81.9%) infants with SCD and 105 (18.1%) infants with other 
hemoglobinopathies. The 5-year incidence of infants with hemoglobin disorders was 90.75 per 
100,000 live births screened in North Carolina, resulting in a detection rate of 1 in 1,102 births 
annually. There was no significant difference between the years. 
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Although the detection of non-sickling hemoglobinopathies was less frequently identified 
through newborn screening, the incidence of these other hemoglobinopathies was 16.43 per 
100,000 infants or 1 in 6,087 newborns screened (Table 1). In the 105 cases, FE (51%) was the 
most common pattern identified mainly of Asian descent, followed by FC (40%) in blacks.  Most 
of these cases were found to be benign conditions. However, a mixture of β-thalassemia zero 
with variants such as Hb E, C, and D are typically associated with clinically significant 
conditions (American College of Medical Genetics and Genomics, 2012; St. Jude Children's 
Research Hospital, 2012). All infants of FF pattern on the NBS are immediately referred for 
confirmatory testing to determine probable diagnosis. There were 2 known cases of β -
thalassemia major identified in this cohort. 
 





No. screened (%) 
(N = 639,115) 
Incidence 
(per 100,000 screened) 
Detection 
Rate 
Sickle cell disease 475 (82%) 74.32 1:1,346 
        FS 336 (58%) 52.57 1:1,902 
        FSC 130 (22%) 20.34 1:4,916 
        FSA 2 (0.3%) 0.31 1:319,558 
        FSE 2 (0.3%) 0.31 1:319,558 
        FSV 5 (0.9%) 0.78 1:127,823 
Other hemoglobin disease 105 (18%) 16.43 1:6,087 
        FE 54 (9%) 8.45 1:11,835 
        FC 42 (7%) 6.57 1:15,217 
        FCV 1 (0.2%) 0.16 1:639,115 
        FF 5 (0.9%) 0.78 1:127,823 
        FV 3 (0.5%) 0.47 1:213,038 
Total 580 (100%) 90.75 1:1,102 
a 
Disease interpretation for FS and FSA indicates SS, S/β
0
-thalassemia, S/HPFH, or S/β
+
-thalassemia, FE indicates 
EE or E/β-thalassemia, FC indicates CC or C/β-thalassemia, FF indicate possible beta thalassemia major or beta 
thalassemia/HPFH, and V indicates variants of D-Los Angeles, Lepore, O-Arab 
Sources: North Carolina State Laboratory of Public Health 
 
 
As shown in Table 1, hemoglobin patterns associated with SCD identified and followed 
as part of this study were 74.32 per 100,000 infants screened, with a detection rate of 1 in 1,346 
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North Carolina births. Of the 475 infants with these sickling conditions detected during this birth 
cohort timeframe, 71% had an FS pattern, 27% had FSC, 0.4% had FSA, 0.4% had FSE, and 1% 
had FSV. While there was no difference by gender in the incidence of SCD, these data 
demonstrated that the occurrence of SCD affects a much higher percentage of black births than 
other races and ethnicities combined (92% vs. 8%, p<0.001). Thus in North Carolina, the 
incidence of SCD identified in black births, 1 in 343 newborns, was 1.5 times higher than the 
national incidence of 1 in 500 African American births (CDC, 2011). The study found that the 
rates of SCD are 103.9 times higher among black births, 16.4 times higher among American 
Indians births and 6.8 times higher among Hispanic births than among white births. Hispanic 
infants (4%) were the second common category of cases identified with SCD (Table 2). Ethnicity 
identified through NBS is based on self-reported data by the mother who classified herself as 
Hispanic at the time of birth. 
 


















FS 309 (1:484) 3 (1:118,742) 2 (1:4,331) 2 (1:447) 20 (1:5,230) 
FSC 124 (1:1,207) 5 (1:71,245) 1 (1:8,662) 0 0 
FSA 2 (1:74,837) 0 0 0 0 
FSE 1 (1:149,674) 0 0 1 (1:893) 0 
FSV 1 (1:149,674) 2 (1:178,113) 1 (1:8,662) 1 (1:893) 0 
Total 437 (1:343) 10 (1:35,623) 4 (1:2,166) 4 (1:223) 20 (1:5,230) 
*
Based on the number of North Carolina live births screened: Blacks, N=149,674; White, N=356,226; American 
Indian, N=8,662; Other (more than 1 race), N= 893; Hispanic, N=104,594  
Sources: North Carolina State Laboratory of Public Health and North Carolina State Center for Health Statistics 
 
Altogether of the 475 infants with SCD identified by newborn screening, 457 (96.2%) 
were analyzed in the initiation of penicillin prophylaxis by 3 months of age. These infants were 
followed by the NCSCSP educator counselors and referred to a comprehensive sickle cell clinic 
(Table 3). Of this cohort, 408 (89.3%) of infants were seen and started penicillin prophylaxis by 
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3 months of age, and 28 (6.1%) by 6 months of age. There were 21 (4.6%) infants that were 
delayed in the initiation of penicillin by the age of one year and older. No documentation was 
available for why there was a delay in starting penicillin after diagnosis. These data also 
documented that the ages at time of treatment and follow-up ranged from birth to 1.5 years 
(median age, 5 weeks). Over the 5 year period, 18 (3.8%) of the infants were not followed by the 
NCSCSP, despite numerous efforts by the educator counselors to contact the parents; 13 infants 
were “lost to follow-up”, 3 infants’ parents refused, 1 infant died, and 1 infant relocated. 
 














Infants with SCD identified through 
the newborn screening program 
 
96 90 106 90 93 475 
Infants followed by the NCSCSP 86(90%) 86(96%) 105(99%) 89(99%) 91(98%) 457(96.2%) 
Infants not followed by the 
NCSCSP 
10(10%) 4(4%) 1(1%) 1(1%) 2(2%) 18(3.8%) 
Age at initiation of treatment and 
follow-up: 
      
     3 months 
 
74(77%) 81(90%) 93(88%) 77(86%) 83(89%) 408(89.3%) 
     6 months 8(8%) 1(1%) 5(5%) 10(10%) 4(4%) 28(6.1%) 
     1 years and older 4(4%) 4(4%) 7(7%) 2(2%) 4(4%) 21(4.6%) 
Sources: North Carolina State Laboratory of Public Health and the NCSCSP database system, WCSWeb 
 
 Figure 1 demonstrates the average time for initiation of penicillin prophylaxis by regions 
served by educator counselors. The routine standard of care in placing these infants on penicillin 
was high. The overall average days to treatment was significantly less than the state program 
guideline, 52 days vs. 90 days, p<0.001. This reflects effective practice and delivery in the 
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follow-up process during this 5-year period of the NCSCSP. There was no significant difference 
in the average days to treatment among the 5 years. However, there was a highly significant 
difference among the regions when comparing the time to initiate penicillin within 3 months and 
not within 3 months (89.3% vs. 10.7%, p=0.002). Further it was found that four regions had 
more than 10% of SCD infants that were outside the standard of care to initiate treatment within 
3 months. Since initiation of penicillin prophylaxis usually requires referral and enrollment into a 
specialty clinic or being seen by a hematologist, the start date of penicillin indirectly indicates 





During this 5 year period, 7 deaths (1.5%) were reported among the 475 infants identified 
with SCD in North Carolina. All of the deaths were among blacks and occurred in FS and FSC 
infants. The mean age at death for the 7 infants was 10 months and the range was from 1 month 




























Figure 1: Average days to initiate penicillin treatment by North 
Carolina Regions, 2005-2009 
Overall Average, 52.18 days 
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infants died of sudden infant death syndrome (SIDS), 1 died of multiple health conditions, 1 died 
of trauma, and 1 died of an unknown virus. Only one of the deaths (0.2%) was likely a SCD-
related mortality, with the cause of death related to pneumonia. This child who died at 9 months 
of age had been administrated penicillin prophylaxis and remained on penicillin until her/his 
death.  
DISCUSSION 
 Universal newborn screening for hemoglobinopathies is the first step to detect blood 
disorders that are life-threatening to children. While early detection and intervention alone has 
proven to significantly reduce the morbidity and mortality of infants with SCD, ensuring 
appropriate follow-up care is of great importance (NIH, 1987; Sickle Cell Disease Guideline 
Panel, 1993; AAP, 2002). Mainly, penicillin prophylaxis therapy has been demonstrated to be an 
effective prevention measure against pneumococcal infections in children with SCD. Therefore, 
there is a need to advocate for increase knowledge and awareness of penicillin treatment as well 
as it becomes part of routine parental education as a mechanism for deceasing complication and 
improving the health of children with SCD. The NIH clinical guidelines for the management of 
sickle cell diseases state, “penicillin prophylaxis should begin by 2 months of age for infants 
with suspected sickle cell anemia, whether or not the definitive diagnosis has been established” 
(NIH, 2002). Realizing that the incidence of Streptococcus pneumonia infection can occur in 
infants as early as 4 months of age, the  NCSCSP developed a similar guideline to ensure that the 
timely follow-up of all newborns diagnosed with SCD are place on oral prophylaxis by 3 months 
of age (Appendix B). 
 The findings from this study presented information about a recent North Carolina cohort 
of infants with SCD and has demonstrated the benefits of newborn screening and early 
intervention in improving survival. During the 5-year period, the screening program identified 
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82% of infants with SCD who were residents of North Carolina and of these infants 96.2% were 
followed by the NCSCSP. As stated above, the incidence of SCD among North Carolina black 
births from 2005 to 2009 was 1 in 343 which is higher than the national incidence of 1 in 500 
black births (CDC, 2011).  In comparison with another state, a most recent study in the birth 
cohorts of Western New York estimated that the incidence of SCD over 27 years among 
newborns is 1 in 615 black births (Lerner et al., 2009) which are lower than North Carolina. 
There was also no significant change in incidence rate over time in both North Carolina and 
Western New York, possibly implying that people are not aware of their carrier status or people 
may choose to exercise their reproductive choice.  
Mortality due to SCD-related death was 0.2% among this cohort. Despite administration 
of penicillin prophylaxis, pneumococcal infection was the cause of one death. However, the 
percentage of infants among this North Carolina cohort who died is lower compared to SCD 
children during the first three years of life described in the other reported cohort studies (0.2% 
vs. 1%) (CDC, 1998; King, et al., 2007; Quinn, Rogers, McCavit, & Buchanan, 2010).  The low 
mortality found in this North Carolina cohort is suggestive of the importance of preventive 
measures such as penicillin prophylaxis by reducing life-threatening complications of SCD in 
infancy.  At best, universal NBS for hemoglobinopathies with the guidelines for penicillin 
therapy provided to PCP and early management of infections may be factors largely attributed to 
increase survival and health development of children with SCD in North Carolina.  
Although the majority of the infants (89.3%) were placed on penicillin by 3 months of 
age, there were still 10.7% of infants who did not received penicillin until after 3months. 
According to the current guideline, penicillin prophylaxis should be started by the ages of two to 
four months in infants with suspected SCD (NIH, 2002). Even though there was no 
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documentation for the delay, there are studies that found some primary care physicians are not 
prepared to manage the follow-up care of children with a positive newborn screen of sickle cell 
disease (Wurst & Sleath, 2004; Michlitsch, Azimi, Hoppe, Walters, Lubin, Lorey, Vichinsky, 
2009). Even if most of these physicians have had an infant with a positive newborn screen, 
Wurst & Sleath found that physicians are not well-informed to discuss the conditions, symptoms, 
and recommended care. Unfortunately, some parents of infants born with SCD were advised by 
their child’s physicians not to initiate the treatment early.  The basis for these decisions is not 
known at this time. However, there are reasons postulated as to why physicians do not prescribe 
treatment, such as physician’s knowledge on up-to-date therapies and/or physician practice 
patterns (Wurst & Sleath, 2004).    
In addition to starting penicillin after 3 months, 3.8% of these infants were not followed. 
Since follow-up of newborns with abnormal hemoglobin disorders must be completed, the 
timeliness in which these infants receive appropriate care is very important. There are factors 
that may contribute to these infants not being followed. One explanation for the majority of the 
infants “lost to follow-up” may be due to lack of correct locating information (Miller, Stilerman, 
Rao, Abhyankar, & Brown, 1990) which can make it difficult for regional educator counselors to 
refer the children and their family to appropriate medical care. In addition to correct locating 
addresses, two North Carolina regions, Regions 10 and 11, cover two large military bases which 
could also be problematic for educator counselors working with a population that is young and 
more mobile.  It should be noted that 10% of these infants lost to follow-up were born during 
2005 and that this rate declined in subsequent years. Further studies should be pursued to 
determine if these infants are truly lost to follow-up. 
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Another factor that also contributes to not being followed is parent refusal or denial. 
Some parents’ health and spiritual beliefs might have an impact on how they perceived and acted 
upon the significant of treatment and care. In a study by Meyappan (2001), some mothers seem 
to have an unclear view on what SCD actually means to them or their children: “In one situation, 
a mother had said that her child was not diagnosed with sickle cell until he was four months old 
and in the hospital with complications that arose from the disease”. In spite of knowing about 
sickle cell, the mother only understood the effects of the disease after the child exhibited 
recurring symptoms (Meyappan, 2001).   Hence, the extent to which the parent/family is able to 
cope with and adjust to the child’s disease influences when the child receives follow-up care.  
Thus, parental education and counseling are important components of the NCSCSP services. 
Education and counseling is needed to assure that parents and families understand the 
implication of hemoglobin diseases and complications. This service is usually offered by 
regional educator counselors and includes the importance of penicillin therapy, vaccinations, and 
regular health care visits. In addition, the educator counselors provide parents/families with a 
NBS kit that has a variety of printed educational materials; one in particular is a comprehensive 
manual from the California Department of Public Health called A Parent’s Handbook for Sickle 
Cell Disease, Part 1: Birth to Six Years of Age, to reinforce education and counseling. The 
NCSCP found that this handbook is a good teaching and reference tool for parents with SCD 
children. The manual is written in clear lay language, covers the essential facts, and illustrates 
key points about SCD and its common symptoms. Previous studies showed that the effectiveness 
of educational efforts (i.e. materials, manuals, and counseling) in regards to the risk of infection 
and the preventive role of penicillin are associated with increased knowledge linked to observed 
improvement in care (Day, Brunson, & Wang, 1992; Mahat, Scoloveno, & Donnelly, 2007).   
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As with any continuous medication regimens, maintaining compliance can be difficult. 
To address this issue, the NCSCSP provides services to ensure that these infants actually receive 
their prescribed penicillin regimen until age five. In the early months of the infant’s life, the 
parents/caregivers are scheduled more regularly for clinic visits. Additionally, the program 
requires that each regional educator counselors conduct a minimum of two home visits per year 
with children from birth to 18 years of age in order to monitor their health care needs and remind 
parents of the benefits of daily penicillin adherence, from 3 months to 5 years of age, at each 
visit (Harris & Leather, 1998). Even though the North Carolina regions were found to have an 
overall average of 52 days to initiate treatment during the 5 year study period, compliance can be 
a complex process to assess by counselors and providers. Obviously, compliance with penicillin 
can be problematic if children do not take penicillin as prescribed putting them at an increased 
risk for infections.  Previous studies have reported that adherence of penicillin prophylaxis 
resulting in pneumococcal sepsis and death were often low (Teach, Lillis, & Grossi, 1998; 
Berkovith, Papadouris, Shaw, Onuaha, Dias, & Olivieri, 1998; Elliott, Morgan, Day, Mollerup, 
&Wang, 2001).  Thus with routine six month assessments and educational efforts by the regions, 
the NCSCSP hopes that prophylactic penicillin compliance can be achieved. 
There are some potential limitations of this study. First, only initial NBS results were 
extracted from the SLPH, since I was unable to capture complete information on confirmatory 
diagnostic results. Several follow-up NBS tests were completed using the SLPH, private 
laboratories, or medical centers laboratories.  In this sample of infants, I could not verify if this 
service was actually provided and whether it verified the outcome of the initial screening (i.e. 
identification of a false positive).  Additional studies are needed to evaluate what percentage of 
the initial NBS samples were returned to the SLPH for confirmatory testing, and to determine 
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which method is the most effective. A second limitation is that penicillin data only reflect an 
indicator of early intervention. This approach was chosen to analyze the time penicillin 
prophylaxis was initiated, not to convey compliance of treatment. Further studies would be 
needed to assess compliance with penicillin prophylaxis for infants identified with SCD in this 
cohort. Lastly, the infants not followed by the program represented potential bias of the data. A 
relatively small number of these infants (3.8%) were not followed because of lack of locating 
information or refusal of treatment. This group might represent an ascertainment bias of the 
NCSCSP, suboptimal outcome of penicillin treatment, and an increased risk for infection. Thus, 
it is slightly possible a different pattern may have been obtained if these infants were available 
for inclusion in the analyses. 
RECOMMENDATIONS  
The findings in this report reinforce the need to incorporate specific recommendations 
based on initiatives already in place by the American Academy of Pediatrics (2002). These 
systems have been shown to make measurable differences and are adaptable to the NCSCSP care 
coordination model. To embark on improving long-term follow-up care throughout the lifespan 
of affected infants with SCD, key features that should facilitate this effort include 
multidisciplinary care system, health promotion and awareness, preventive care, and surveillance 
and evaluation.   
1. Provide a multidisciplinary care system through health care providers, hematologists, 
nurses, social workers, and educator counselors to improve and maintain health care of 
infants affected with SCD.  These infants should have regular health visit every 2-4 
months (AAP, 2002) up to age 2 years, then every 6 months thereafter through a medical 
home and ensure quality of care. An integrated goal of the entire system should be the 
coordination of follow-up activities to achieve optimal health and outcomes. 
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2. Increase health promotion and awareness of educational interventions for adherence to 
treatments through evidence-based strategies such as reminders and parental education. 
Health providers of children with SCD should play an important role in reinforcing 
regular administration of penicillin and counseling parents about concerns at home. In 
addition, public health efforts are needed to explore parent’s belief, social, and 
environmental factors regarding penicillin (Elliott et al, 2001). 
3. Penicillin prophylaxis treatment, initiated by NBS, is a recognized standard of preventive 
care for children with SCD (Gaston et al, 1986).  State health department should adopt 
regulations or guidelines to direct preventive services. For instance, the NCSCSP 
provides funding to six comprehensive medical centers and requires that penicillin be 
given to infants identified with SCD through NBS (NCSCSP, 2010). However, additional 
studies are still needed to determine the long-term effects of penicillin prophylaxis 
initiated early in infants. A key component that should be considered is the increased risk 
of emergence of penicillin-resistant Streptococcus pneumonia which has increased over 
time in the U.S. (Cober & Phelps, 2010). 
4. Develop integrated public health surveillance and monitoring system to better coordinate 
care such as appropriate follow-up, assessments, referrals, and delivery of services 
relating to SCD and other hemoglobin disorders. This system would allow continuous 
evaluation and improvement of the statewide program as well as support further research. 
Currently in North Carolina, there is a link between the NBS and NCSCSP database 
systems, and a poor link between medical centers systems where infants are usually 
enrolled. Collecting and integrating data will help provide knowledge about these 
disorders and support decision-making policies. 
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5. Provide opportunities for continuing education credits and units to health care providers 
such as primary care physicians, specialty physicians, emergency room physicians, 
nurses, nurse practitioners, physician assistants, medical students, social workers, and 
others who regularly interact with people (and families) who have SCD to improve these 
providers’ knowledge and awareness of up-to-date SCD management. These educational 
strategies should be developed to encourage providers to adopt new standards of care for 
SCD over the lifespan. The protocols and guidelines for care should also supplement 
current practices. 
CONCLUSION 
Penicillin prophylaxis has been shown to reduce the incidence of life-threatening 
infections in young children with SCD. Since SCD is a lifelong chronic disorder, long-term 
follow-up is required to improve optimal health outcomes. However, it is worth noting that NBS 
to detect hemoglobinopathies remains the cornerstone of public health practice for early 
detection and intervention. Timely and sustainable use of penicillin for infants with SCD seems 
imperative from both clinical and economical viewpoints. The findings from this study support 
the use of universal NBS and early intervention of penicillin prophylaxis within 3 months of age.  
A significantly different rate of early intervention was found among the 13 regions in North 
Carolina. However, the overall incidence of SCD in North Carolina from 2005 to 2009 has not 
changed over time. This information can be of value to the leadership of both the NCSCSP and 
the medical centers in developing a greater focus on the importance of trait counseling, as well as 
education concerning the role of NBS and the importance of prophylactic penicillin for infants 
with SCD. Therefore, these are key steps suggested for state-wide preventive strategies in 
reducing mortality and morbidity in children with SCD and other hemoglobin disorders.  
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The following guidelines for the administration of prophylactic penicillin in treating 
infants with sickle cell disease have been expanded to include the administration of 
penici1lin to infants with Hemoglobin SC (FSC), Hemoglobin SD (FSD), Hemoglobin 
SOArab (FSOArab) etc. and other forms of sickle cell disease.   These forms of sickle cell 
disease are also associated with an increased risk of pneumococcal infections. The 
guidelines previously recommended the administration of penicillin to infants with an FS 
pattern only on newborn screening. 
 
 
PROGRAM GUIDELINES FOR THE ADMINISTRATION 
OF PROPHYLACTIC PENICILLIN 
 
 
These guidelines have been developed by the pediatric hematologists at comprehensive 
sickle cell medical centers in North Carolina. The North Carolina Sickle Cell Program 
and the Governor’s Council on Sickle Cell strongly encourage compliance with these 
guidelines by all primary care providers providing care to children with different forms of 
sickle cell disease. A copy of these guidelines is sent by the State Laboratory of Pub1ic 
Health to each provider whose name appears on the newborn screening form of infants 





Why administer penicillin? 




One of the major advances in the care of infants with sickle cell disease has been the 
recognition that oral penicillin given twice a day will significantly reduce morbidity and 
mortality from pneumococcal infections (Gaston, Verter, Woods and colleagues, 1986). It 
is therefore imperative that the physician caring for a child with sickle cell disease 
establish a definitive diagnosis, provide appropriate education and counseling to the 
child's parents and family, and begin penicillin prophylaxis.  Due to time constraints, 
local physicians frequently refer families to a sickle cell educator/counselor for education 
and counseling.  Please refer to the attached list for geographic areas of coverage, names, 
and telephone numbers. In instances where the definitive diagnosis cannot be determined, 
an infant with the FS genotype should be maintained on prophylactic penicillin until a 
definitive diagnosis is established. The importance of administering the prophylactic 
antibiotics should be stressed at all visits because parents might become lax or less 
focused over time in dispensing this essential treatment. 
 
Who should receive penicillin? 
 
Based on guidelines published by the National Institutes of Health, ALL infants 
identified with sickle cell disease through newborn screening should receive twice daily 
penicillin prophylaxis. This includes infants with FS genotype (indicating a likely 
diagnosis of sickle cell anemia (Hemoglobin SS) or Hemoglobin S/β-thalassemia), FSC 
genotype and other forms of sickle cell disease including Hemoglobin SD, Hemoglobin 
SOArab, etc. because infants with all forms of sickle cell disease are at an increased risk of 
infection.  
 
How long should penicillin be administered? 
 
Prophylactic penicillin is recommended for all patients with sickle cell disease beginning 
at age two to three months. Patients with Hemoglobin SS or Hemoglobin S/β
o
-
thalassemia can discontinue this medication at age five unless they have had a 
splenectomy or severe past history of pneumococcal infection. Although final guidelines 
for the length of time to administer penicillin to patients with Hemoglobin SC and other 













2 month to 3 years 
3 years to 5+ years 
 
 
Penicillin VK 125 mg po bid 
Penicillin VK 250 mg po bid 
 
Erythromycin (EES) 
20 mg/kg/d ÷ bid (both ages) 
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For more information contact: 
 
U.S. Department of Health and Human Services          
National Institutes of Health              
National Heart, Lung, and Blood Institute    
P.O Box 30105              
Bethesda, MD 20824              
Phone: (301) 592-8573             
Web: http:/www.nhlbi.nih.gov            
 
NC Department of Health and Human Services 
Division of Public Health 
NC Sickle Cell Syndrome Program 
1929 Mail Service Center 
Raleigh, NC 27699 




Comprehensive Sickle Cell Medical Centers 
 
Mission Hospital, Asheville, NC     828-213-9770  
Carolinas Medical Center, Charlotte, NC    704-381-9900 
WFU Baptist Medical Center, Winston-Salem, NC   336-713-5930 
UNC Chapel Hill School of Medicine, Chapel Hill, NC  919-966-0178 
Duke University Medical Center, Durham, NC   919-684-3401 
ECU Brody School of Medicine, Greenville, NC   252-744-4676 
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